|
1
|
DE Luca A, Frusone F, Vergine M, Cocchiara
R, LA Torre G, Ballesio L, Monti M and Amabile MI: Breast cancer
and multiple primary malignant tumors: Case report and review of
the literature. In vivo. 33:1313–1324. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao J, Tan Y, Wu Y, Zhao W, Wu J, Ji M,
Shi L, Jiang J and Wu C: A rare case of eight multiple primary
malignant neoplasms in a female patient: A case report and review
of the literature. Oncol Lett. 9:587–590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mukaiyama Y, Suzuki M, Morikawa T, Mori Y,
Takeshima Y, Fujimura T, Fukuhara H, Nakagawa T, Nishimatsu H, Kume
H and Homma Y: Multiple primary malignant neoplasms of the glottis,
renal pelvis, urinary bladder, oral floor, prostate, and esophagus
in a Japanese male patient: A case report. World J Surg Oncol.
12:2942014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang H, Hou J, Zhang G, Zhang M, Li P, Yan
X and Ma Z: Clinical characteristics and prognostic analysis of
multiple primary malignant neoplasms in patients with lung cancer.
Cancer Gene Ther. Jan 31–2019.(Epub ahead of print). View Article : Google Scholar
|
|
5
|
Lee J, Park S, Kim S, Kim J, Ryu J, Park
HS, Kim SI and Park BW: Characteristics and survival of breast
cancer patients with multiple synchronous or metachronous primary
cancers. Yonsei Med J. 56:1213–1220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mochizuki T, Teraoka A, Akagawa H, Makabe
S, Akihisa T, Sato M, Kataoka H, Mitobe M, Furukawa T, Tsuchiya K
and Nitta K: Mutation analyses by next-generation sequencing and
multiplex ligation-dependent probe amplification in Japanese
autosomal dominant polycystic kidney disease patients. Clin Exp
Nephrol. 23:1022–1030. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kataoka Y, Hirano K, Narabayashi T, Hara
S, Fujimoto D, Tanaka T, Ebi N, Tomii K and Yoshioka H: Concordance
between the response evaluation criteria in solid tumors version
1.1 and the immune-related response criteria in patients with
non-small cell lung cancer treated with nivolumab: A multicenter
retrospective cohort study. Cancer Chemother Pharmacol. 81:333–337.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han Y, Shao N, Xi X and Hao X: Use of
microwave ablation in the treatment of patients with multiple
primary malignant tumors. Thoracic Cancer. 8:365–371. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Warren S and Gates O: Multiple primary
malignant tumors: A survey of the literature and statistical study.
Am J Cancer. 16:1358–1414. 1932.
|
|
10
|
Etiz D, Metcalfe E and Akcay M: Multiple
primary malignant neoplasms: A 10-year experience at a single
institution from Turkey. J Cancer Res Ther. 13:16–20. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Motuzyuk I, Sydorchuk O, Kovtun N, Palian
Z and Kostiuchenko Y: Analysis of trends and factors in breast
multiple primary malignant neoplasms. Breast Cancer (Auckl).
12:1178223418759952018. View Article : Google Scholar
|
|
12
|
Parekh JD, Kukrety S, Thandra A and
Valenta C: Multiple primary malignant neoplasms in an elderly
patient. Cureus. 10:e23842018.PubMed/NCBI
|
|
13
|
Huss S, Pasternack H, Ihle MA,
Merkelbach-Bruse S, Heitkötter B, Hartmann W, Trautmann M,
Gevensleben H, Büttner R, Schildhaus HU and Wardelmann E:
Clinicopathological and molecular features of a large cohort of
gastrointestinal stromal tumors (GISTs) and review of the
literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rere
events. Hum Pathol. 62:206–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang Y, Meng Y, Zhang H, Shen X, Li R, Yu
L, Liu B and Wang L: Detection of EGFR and BRAF mutations by
competitive allele-specific TaqMan polymerase chain reaction in
lung adenocarcinoma. Oncol Lett. 15:3295–3304. 2018.PubMed/NCBI
|
|
15
|
Mitsogianni M, Mitsimponas N, Crespo F,
Hartmann KA, Klosterhalfen B, Haase S and Giagounidis A:
Concomitant non-small cell lung cancer and hairy cell leukemia in a
patient harboring BRAF-V600E mutation in both tissues: A case
report. Case Rep Oncol. 11:109–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ding X, Zhang Z, Jiang T, Li X, Zhao C, Su
B and Zhou C: Clinicopathologic characteristics and outcomes of
Chinese patients with non-small-cell lung cancer and BRAF mutation.
Cancer Med. 6:555–562. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khunger A, Khunger M and Velcheti V:
Dabrafenib in combination with trametinib in the treatment of
patients with BRAF V600-positive advanced or metastatic non-small
cell lung cancer: Clinical evidence and experience. Ther Adv Respir
Dis. 12:17534666187676112018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mufti M, Ching S, Farjami S, Shahangian S
and Sobnosky S: A case series of two patients presenting with
pericardial effusion as first manifestation of non-small cell lung
cancer with BRAF mutation and expression of PD-L1. World J Oncol.
9:56–61. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weart TC, Miller KD and Simone CB 2nd:
Spotlight on dabrafenib/trametinib in the treatment of
non-small-cell lung cancer: Place in therapy. Cancer Manag Res.
10:647–652. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim TJ, Hong SA, Kim O, Kim SJ, Yang JH,
Joung EK, Kang JH and Hong SH: Changes in PD-L1 expression
according to tumor infiltrating lymphocytes of acquired EGFR-TKI
resistant EGFR-mutant non-small-cell lung cancer. Oncotarget.
8:107630–107639. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Su S, Dong ZY, Xie Z, Yan LX, Li YF, Su J,
Liu SY, Yin K, Chen RL, Huang SM, et al: Strong programmed death
ligand 1 expression predicts poor response and de novo resistance
to EGFR TKIs among non-small cell lung cancer patients with EGFR
mutation. J Thorac Oncol. 13:1668–1675. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J
and Hodi FS: The activation of MAPK in melanoma cells resistant to
BRAF inhibition promotes PD-L1 expression that is reversible by MEK
and PI3K inhibition. Clin Cancer Res. 19:598–609. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li SD, Martial A, Schrock AB and Liu JJ:
Extraordinary clinical benefit to sequential treatment with
targeted therapy and immunotherapy of a BRAF V600E and PD-L1
positive metastatic lung adenocarcinoma. Exp Hematol Oncol.
6:292017.PubMed/NCBI
|
|
24
|
Liu J, Chen Z, Chen H, Hou Y, Lu W, He J,
Tong H, Zhou Y and Cai W: Genetic polymorphisms contribute to the
individual variations of imatinib mesylate plasma levels and
adverse reactions in chinese GIST patients. Int J Mol Sci. 18(pii):
E6032017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Peixoto A, Costa-Moreira P, Silva M,
Santos AL, Lopes S, Vilas-Boas F, Moutinho-Ribeiro P and Macedo G:
Gastrointestinal stromal tumors in the imatinib era: 15 years'
experience of a tertiary center. J Gastrointest Oncol. 9:358–362.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sanchez-Hidalgo JM, Duran-Martinez M,
Molero-Payan R, Rufian-Peña S, Arjona-Sanchez A, Casado-Adam A,
Cosano-Alvarez A and Briceño-Delgado J: Gastrointestinal stromal
tumors: A multidisciplinary challenge. World J Gastroenterol.
24:1925–1941. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rubin BP: Gastrointestinal stromal
tumours: An update. Histopathology. 48:83–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Balachandran VP and Dematteo RP:
Gastrointestinal stromal tumors: Who should get imatinib and for
how long. Adv Surg. 48:165–183. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Alecu L, Tulin A, Enciu O, Bărbulescu M,
Ursuţ B and Obrocea F: Gastrointestinal stromal tumors-Diagnosis
and surgical treatment. Chirurgia (Bucur). 110:525–529.
2015.PubMed/NCBI
|
|
30
|
Mei L, Du W, Idowu M, von Mehren M and
Boikos S: Advances and challenges on management of gastrointestinal
stromal tumors. Front Oncol. 8:1352018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Joensuu H, Eriksson M, Sundby Hall K,
Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster
J, Al-Batran SE, et al: One vs three years of adjuvant imatinib for
operable gastrointestinal stromal tumor: A randomized trial. JAMA.
307:1265–1272. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Vita A, Recine F, Mercatali L,
Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A,
Pieri F, Riva N, et al: Myxofibrosarcoma primary cultures:
Molecular and pharmacological profile. Ther Adv Med Oncol.
9:755–767. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Colia V, Fiore M, Provenzano S, Fumagalli
E, Bertulli R, Morosi C, Dei Tos AP, Barisella M, Gronchi A, Casali
PG and Sanfilippo R: Activity of anthracycline- and
ifosfamide-based chemotherapy in a series of patients affected by
advanced myxofibrosarcoma. Clin Sarcoma Res. 7:162017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wong A, Chan Woo Park R, Mirani NM and
Eloy JA: Myxofibrosarcoma of the maxillary sinus. Allergy Rhinol
(Providence). 8:e95–e99. 2017. View Article : Google Scholar
|
|
35
|
Tsuchie H, Kaya M, Nagasawa H, Emori M,
Murahashi Y, Mizushima E, Miyakoshi N, Yamashita T and Shimada Y:
Distant metastasis in patients with myxofibrosarcoma. Ups J Med
Sci. 122:190–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lohberger B, Stuendl N, Leithner A, Rinner
B, Sauer S, Kashofer K and Liegl-Atzwanger B: Establishment of a
novel cellular model for myxofibrosarcoma heterogeneity. Sci Rep.
7:447002017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nomura T, Sakakibara S, Moriwaki A,
Kawamoto T, Suzuki S, Ishimura T, Hashikawa K and Terashi H:
Terashi, low-grade myxofibrosarcoma of the rectus abdominus muscle
infiltrating into abdominal cavity: A case report. Eplasty.
17:e62017.PubMed/NCBI
|
|
38
|
Yamazaki N, Tsutsumida A, Takahashi A,
Namikawa K, Yoshikawa S, Fujiwara Y, Kondo S, Mukaiyama A, Zhang F
and Kiyohara Y: Phase 1/2 study assessing the safety and efficacy
of dabrafenib and trametinib combination therapy in Japanese
patients with BRAF V600 mutation-positive advanced cutaneous
melanoma. J Dermatol. 45:397–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dy GK and Adjei AA: Understanding,
recognizing, and managing toxicities of targeted anticancer
therapies. CA Cancer J Clin. 63:249–279. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ghias AAP, Bhayani S, Gemmel DJ and Garg
SK: Rapidly progressive dyspnea in gastrointestinal stromal tumor
(GIST) with imatinib cardiac toxicity. J Community Hosp Intern Med
Perspect. 8:87–91. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Drilon A, Laetsch TW, Kummar S, DuBois SG,
Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo
AS, et al: Efficacy of larotrectinib in TRK fusion-positive cancers
in adults and children. N Engl J Med. 378:731–739. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Noy A, de Vos S, Thieblemont C, Martin P,
Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S,
et al: Targeting Bruton tyrosine kinase with ibrutinib in
relapsed/refractory marginal zone lymphoma. Blood. 129:2224–2232.
2017. View Article : Google Scholar : PubMed/NCBI
|
